LONDON (Alliance News) - Sareum Holdings PLC said Friday that Sierra Oncology Inc reported preclinical efficacy data for an immunotherapy combination with its SRA737 inhibitor in lung licences the Read More
LONDON (Alliance News) - Sareum Holdings PLC said Friday it raised GBP850,000 via the issue of 130.8 million shares to fund the development of its lead cancer and autoimmune drugs.The drug Read More
LONDON (Alliance News) - Sareum Holdings PLC on Monday said it swung to an annual loss after reporting a substantial share of profit from associates the year before.Shares in Sareum were at Read More
LONDON (Alliance News) - Sareum Holdings PLC said Wednesday that it has selected the SDC-1802 molecule from the TYK2 inhibitor programme for further development as potential treatment for certain Read More
LONDON (Alliance News) - Sareum Holdings PLC said Tuesday it expects to report a loss in its annual results as it progresses on its programmes in autoimmune diseases and cancer.The drug it Read More
LONDON (Alliance News) - Sareum Holdings PLC said Monday it will develop SDC-1801 as a possible treatment for autoimmune diseases.The molecule, SDC-1801, has been formally selected for is a Read More
LONDON (Alliance News) - Sareum Holdings PLC said on Thursday that it has regained its worldwide rights to a potential treatment for leukaemia and other blood-related cancers.The drug said Read More
LONDON (Alliance News) - Sareum Holdings PLC said Thursday its development partner Sierra Oncology's SRA737 results have been accepted for presentation at the annual of of Read More
